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ABSTRACT
Introduction: Currently there are no general guidelines for diagnosis or management of suspected drug-
induced (DI) interstitial lung disease (ILD). The objective was to survey a sample of current European
practice in the diagnosis and management of DI-ILD, in the context of the prescribing information
approved by regulatory authorities for 28 licenced drugs with a recognised risk of DI-ILD.
Methods: Consultant physicians working in specialist ILD centres across Europe were emailed two surveys
via a website link. Initially, opinion was sought regarding various diagnostic and management options
based on seven clinical ILD case vignettes and five general questions regarding DI-ILD. The second survey
involved 29 statements regarding the diagnosis and management of DI-ILD, derived from the results of
the first survey. Consensus agreement was defined as 75% or greater.
Results: When making a diagnosis of DI-ILD, the favoured investigations used (other than computed
tomography) included pulmonary function tests, bronchoscopy and blood tests. The preferred method
used to decide when to stop treatment was a pulmonary function test. In the second survey, the majority
of the statements were accepted by the 33 respondents, with only four of 29 statements not achieving
consensus when the responses “agree” and “strongly agree” were combined as one answer.
Conclusion: The two surveys provide guidance for clinicians regarding an approach to the diagnosis and
management of DI-ILD in which the current evidence base is severely lacking, as demonstrated by the limited
information provided by the manufacturers of the drugs associated with a high risk of DI-ILD that we reviewed.
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ORIGINAL ARTICLE
INTERSTITIAL LUNG DISEASE
Introduction
Although the exact number is unknown, at least 450 drugs have been reported to cause interstitial lung
disease (ILD), and this number will likely continue to rise as new medications are developed [1]. The main
categories of medications associated with drug-induced (DI) ILD include chemotherapeutic (e.g.
bleomycin), biological (e.g. infliximab), anti-inflammatory (e.g. methotrexate), antimicrobial (e.g.
nitrofurantoin), cardiovascular (e.g. amiodarone), and miscellaneous agents [2]. Importantly, checkpoint
inhibitors as a class are associated with lung toxicity and use of these agents is increasing [3, 4]. A UK
population-based study published in 2012 estimated that the incidence of drug/radiation-induced ILD
between 1997 and 2008 was 4.1 per million person-years [5]. However, this is likely to be underestimated
due to the increased use of biologics and checkpoint inhibitors over the past decade. The pathogenic
mechanism responsible for the development of DI-ILD in humans is unclear [1]. Animal studies with
drugs known to cause DI-ILD in humans use mainly just one agent, bleomycin [6].
Currently there are no general guidelines regarding the diagnostic and management approach for
suspected DI-ILD. The diagnosis initially involves excluding infection and is particularly challenging due
to the non-specific clinical, histological and radiological findings that can overlap with other ILD subtypes.
Diagnosis of DI-ILD is supported by a temporal link between an exposure to the offending drug and the
development of new respiratory symptoms, signs and/or radiological changes; however, DI-ILD may
develop within the first few days or even several years after the drug was commenced [7]. Furthermore,
drugs used to treat connective tissue diseases (CTDs) can themselves cause DI-ILD, making it difficult to
determine whether the development of ILD is due to the underlying CTD or the drug in question.
Likewise, checkpoint inhibitors may be used in patients with lung cancer who may already have
respiratory symptoms.
When ILD is recognised as a potential adverse effect of a particular drug, regulatory authorities require
this to be specified in the prescribing information. Recently introduced DI-ILD-associated drugs were
generally approved following high-quality trials with exhaustive documentation of adverse events followed
by rigorous regulatory scrutiny, and proportionate, evidence-based drug labelling. However other drugs
were first introduced many decades ago (e.g. nitrofurantoin in 1953) when clinical trial design and
regulatory science were less mature. These older agents are now generic, the evidence base for adverse
effects is more limited, and the prescribing information is seldom updated to reflect the modern-day
practice of respiratory medicine. If DI-ILD is suspected, it is important to consider discontinuation of the
causative agent, and although good quality evidence is lacking, corticosteroids are often commenced.
Improvement of symptoms and radiology usually occurs following discontinuation of the suspected drug.
However, irreversible fibrosis may occur especially if the diagnosis of DI-ILD is delayed.
We report the results of two online surveys with the aim of illustrating current European practice in the
diagnosis and management of DI-ILD. We also summarise current prescribing information regarding the
incidence of DI-ILD, guidance on respiratory monitoring and management of suspected or confirmed
DI-ILD for 28 licenced drugs associated with a recognised risk of DI-ILD. This study was conducted in
order to determine what specific prescribing guidance was available and to compare this to the results of
expert consensus agreement from the surveys.
Methods
Consultant respiratory physicians working in Europe, with a sub-speciality interest in ILD were emailed
two separate surveys, at different time points, via a website link (SurveyMonkey). The surveys were
developed through an iterative process of review by a group of physicians with an interest in ILD. In the
first survey, opinion was sought on 34 case-specific questions regarding seven clinical ILD case vignettes,
exploring various diagnostic and management options. The cases were fictional and based on common
clinical scenarios in ILD with an emphasis on DI-ILD. There were a further five general questions
examining investigations used to diagnose DI-ILD, frequency of patient follow-up, weaning regimens for
corticosteroids (prednisolone) and indications for discontinuation of treatment. The second survey
involved 29 statements regarding diagnosis and management of DI-ILD. These statements were derived
from responses to the first survey with the aim to obtain responses that were likely to achieve consensus
and therefore allow for construction of expert-opinion-based guideline. For each statement, respondents
had the option of choosing one of five choices (strongly agree, agree, neutral, disagree or strongly
disagree). In both surveys, consensus agreement was defined as 75% or greater. Ethics committee approval
was not required because there was no involvement of patients.
The prescribing information from the US Food and Drug Administration (FDA) for 28 licenced drugs
previously identified as being associated with a significant risk of DI-ILD in a systematic review [2] were
reviewed. The FDA is a long-established regulatory agency and publishes approved prescribing information
in consistent formats, whereas prescribing information in European jurisdictions is more difficult to
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review, particularly for older drugs that predate the establishment of the European Medicines Agency
(EMA). The most recent (2018) prescribing information posted at https://www.accessdata.fda.gov/scripts/
cder/daf/index.cfm was used. These 28 drugs were approved between 1953 and 2017 for a variety of
indications. Prescribing information, therefore, reflects vast differences in clinical experience, patterns of
clinical use and duration of post-marketing surveillance. Where possible FDA-approved text was
cross-checked with EMA-approved advice.
Results
Survey 1
34 out of a total of 60 (57%) ILD physicians completed the first survey. Overall, 21 respondents were
based in the UK and 13 were based in other European countries (1 Belgium, 1 Denmark, 2 France,
1 Germany, 4 Italy, 1 Netherlands, 1 Spain, 1 Switzerland and 1 Turkey). Five respondents were excluded
because fewer than 50% of the questions were completed. The responses to the questions and a description
of the clinical cases is in the supplementary material. Of the 34 case-specific questions, consensus was only
achieved once (in case six, 91% of respondents chose RA-ILD as the diagnosis). Consensus was achieved
in two of the five general questions pertaining to investigations and treatment discontinuation. When
making a diagnosis of DI-ILD, the favoured investigations used (other than high resolution computed
tomography (CT)) included pulmonary function tests (PFTs) (91% of respondents), bronchoscopy with
bronchoalveolar lavage for differential cell count and/or microbiology (100% of respondents) and blood
tests including auto-antibody screen (91% of respondents). The preferred methods used to decide when to
stop treatment for DI-ILD included forced vital capacity (FVC) and diffusing capacity of the lung for
carbon monoxide (DLCO) (87% of respondents). Although consensus was not reached, 70% of respondents
used repeat CT and 65% used patients’ symptoms to decide when to stop treatment.
Although no consensus was achieved regarding the management of DI-ILD in clinical cases, the results
suggest some degree of shared practice. A total of 68% of respondents chose prednisolone 0.5 mg·kg−1 for
2–4 weeks reducing by 5 mg every 1–2 weeks as tolerated for the management of DI-ILD. There was no
agreement regarding the optimal dose of intravenous (i.v.) methylprednisolone, with 26% of respondents
choosing 500 mg once daily for 3 days and 26% of respondents choosing 1 g once daily for 3 days.
Following i.v. methylprednisolone, the majority (39%) of respondents selected prednisolone 0.5 mg·kg−1 for
2–4 weeks, reducing by 5 mg every 1–2 weeks as tolerated as their preferred ongoing treatment strategy.
Although no consensus was reached regarding the duration of prednisolone treatment before attempting
dose reduction, the majority of respondents (44%) chose 4 weeks. When “second-line” immunosuppression
was required the majority (40%) of respondents chose i.v. cyclophosphamide with the dose varying from
500 to 750 mg·m−2. Overall, 74% of respondents used both FVC and DLCO to decide when to attempt
weaning the dose of prednisolone, with 13% of respondents using FVC alone. A total of 70% of
respondents used patients’ symptoms and 57% used repeat chest radiography, with 35% using repeat CT to
decide the ideal time to reduce the prednisolone dose. In patients with a diagnosis of DI-ILD, the preferred
frequency of follow-up was 6 weeks (48% of respondents).
Survey 2
33 out of a total of 60 (55%) ILD physicians completed the second survey, with a 100% answer rate.
22 respondents were based in the UK and 11 were based in other European countries (1 Belgium, 1 Czech
Republic, 1 Denmark, 1 France, 1 Germany, 4 Italy, 1 Netherlands, 1 Turkey). 21 of the 33 respondents
also completed the first survey. Consensus (⩾75% of respondents choosing “strongly agree”) was achieved
in five of the 29 statements pertaining to statements regarding clinical suspicion, diagnosis and
management of DI-ILD (table 1). Of the remaining 24 statements, when the responses “agree” and
“strongly agree” were combined, consensus was achieved on 20 occasions (table 2). Therefore, when the
responses “agree” and “strongly agree” were combined only four of the 29 statements did not achieve
consensus (table 3).
Figures 1 and 2 illustrate a proposed DI-ILD diagnostic and treatment algorithm respectively, based on the
consensus statements from the two surveys.
Prescribing information
The results of the prescribing information reviewed are summarised in figure 3 (full details can be found in
table 1 of supplementary material). The classes of drugs described include chemotherapeutic (including
checkpoint inhibitors), biological, anti-inflammatory, antimicrobial (nitrofurantoin) and cardiovascular
(amiodarone). For 27 of 28 drugs, the prescribing information warns of the risk of DI pulmonary toxicity,
variously described as ILD, lung infiltration, pneumonitis, hypersensitivity pneumonitis, interstitial
pneumonitis, alveolar pneumonitis, immune-mediated pneumonitis, non-infective pneumonitis, eosinophilic
pneumonia, bronchiolitis obliterans, organising pneumonia, or pulmonary fibrosis. For three of 27 drugs
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(amiodarone, bleomycin and methotrexate) DI pulmonary toxicity features as a “boxed warning”. In 14 of
27 cases, respiratory monitoring (e.g. symptoms/signs, physiology, radiography) is advised, and in 7 of 14
cases, physicians are specifically advised to use PFTs or radiography in their monitoring. Regular chest
radiography every 1–2 weeks is advised during bleomycin treatment; whereas, chest radiography monitoring
is advised every 3–6 months following the initiation of amiodarone. There was no specific advice regarding
the frequency of PFTs or radiography in the monitoring of the other five drugs. For 18 of 27 drugs, the
patient information leaflet specifically counselled patients to report any change in respiratory symptoms to
their healthcare provider. In 22 of 27 cases, the prescribing information discussed discontinuation in cases
of suspected or confirmed DI-ILD, and of these, 17 of 22 also discussed dose reduction or temporary
discontinuation. 13 of 27 discussed the use of diagnostic imaging tests, and 10 of 27 advised on
corticosteroid use, of which 6 provided specific recommendations for dosage of corticosteroids.
Discussion
Our first survey revealed significant variation amongst ILD experts in the diagnosis and management of
seven different ILD cases. We do not feel that this is surprising given the poor inter-multidisciplinary
meeting agreement in the diagnosis of non-specific interstitial pneumonia and hypersensitivity
pneumonitis reported by WALSH et al. [8], this being indicative of significant interobserver variation within
the field of ILD generally. In our first survey, consensus was achieved in the diagnosis of only one of the
cases and no consensus was reached in the specific management of any case. There appeared to be some
agreement regarding the initial dose and weaning regimen of prednisolone, with the majority of
respondents choosing 0.5 mg·kg−1 for 2–4 weeks reducing by 5 mg every 1–2 weeks as tolerated. The same
prednisolone dose and weaning regimen was preferred following treatment with i.v. methylprednisolone
and the favoured second-line immunosuppressant was i.v. cyclophosphamide. There was consensus
regarding the investigations used to diagnose DI-ILD and when to stop treatment. FVC and DLCO were
the preferred investigations used to decide when to stop DI-ILD treatment and the investigations favoured
by physicians in the diagnosis of DI-ILD included PFTs, bronchoscopy with bronchoalveolar lavage for
differential cell count and/or microbiology and bloods (including auto-antibody screen). Although no
consensus was reached, the preferred duration of prednisolone treatment before attempting dose reduction
was 4 weeks, the majority of respondents favoured the use of both FVC and DLCO to decide when to
attempt weaning the dose of prednisolone. The most common frequency of follow-up for DI-ILD was
6 weeks.
Our second survey focused on multiple statements regarding particular aspects of the diagnosis and
management of DI-ILD, with a view to generating an expert-opinion-defined clinical guideline. The
statements were derived from responses to the initial survey. Five out of the 29 statements achieved
consensus in terms of a response of “strongly agree” (table 1). All five statements relate to the diagnosis of
DI-ILD, suggesting that there is greater agreement between clinicians in the diagnosis of DI-ILD than the
management of DI-ILD. This reflects the lack of evidence-based guidelines on the management of DI-ILD
with ILD clinicians tending to extrapolate from treatment of other ILD subtypes. Consensus regarding the
management of DI-ILD could also be influenced by the heterogeneity of DI-ILD severity and disease
course. The majority of the statements were accepted by the 33 respondents, with only four out of the 29
statements not achieving consensus when the responses “agree” and “strongly agree” were combined as
TABLE 1 Statements achieving consensus (⩾75% of respondents choosing strongly agree)
Statement Responses: strongly agree
DI-ILD should be considered when patients present with respiratory symptoms while receiving treatment with a
drug known to be associated with DI-ILD
30 (91%)
DI-ILD should be suspected if there are radiological and physiological abnormalities emerging in a patient
taking a drug known to cause DI-ILD
28 (85%)
DI-ILD should be strongly suspected if there is a temporal relationship between commencing a drug known to
cause DI-ILD and symptom onset
28 (85%)
When a patient presents with new respiratory symptoms while using a medication known to cause DI-ILD, and
should initial investigations and treatment not resolve the clinical scenario, investigations should include
pulmonary function tests (spirometry and transfer factor)
28 (85%)
When a patient presents with new respiratory symptoms while using a medication known to cause DI-ILD, and
should initial investigations and treatment not resolve the clinical scenario, investigations should include
chest radiography and HRCT scan
28 (85%)
DI-ILD: drug-induced interstitial lung disease; HRCT: high-resolution computed tomography.
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one answer (table 3). Of the four statements that did not reach consensus, two had less than a 50%
response as either “agree” or “strongly agree”. Seven (21%) respondents were neutral and 10 (30%) either
“disagreed” or “strongly disagreed” that when a patient presents with new respiratory symptoms while
using a medication known to cause DI-ILD, initial investigations and management should focus around
more common causes of symptoms. 12 (36%) respondents were neutral and seven (21%) either
TABLE 2 Statements achieving consensus when agree and strongly agree is combined as one answer (excludes the five
statements in table 1)
Statement Responses: agree or
strongly agree
DI-ILD should not be discounted if there is no clear temporal relationship between drug commencement and symptom
onset
27 (82%)
DI-ILD should be considered if an alternative cause of symptoms, abnormal physiology and radiological changes
cannot be identified, or if the patient fails to respond to treatment for the alternative cause
25 (76%)
A diagnosis of DI-ILD should not be made without the involvement of a specialist ILD MDT 28 (85%)
When a patient presents with new respiratory symptoms while using a medication known to cause DI-ILD, and should
initial investigations and treatment not resolve the clinical scenario, investigations should include bronchoalveolar
lavage with samples sent to exclude infection (typical/atypical), should the patient be deemed able to undertake the
procedure
28 (85%)
When a patient presents with new respiratory symptoms while using a medication known to cause DI-ILD, and should
initial investigations and treatment not resolve the clinical scenario, investigations should include bronchoalveolar
lavage with samples examined for differential cell count, should the patient be deemed able to undertake the
procedure
28 (85%)
When a patient presents with new respiratory symptoms while using a medication known to cause DI-ILD, and should
initial investigations and treatment not resolve the clinical scenario, investigations should include blood tests
including tests for infection, to assess underlying comorbid disease activity and to assess the inflammatory
response
28 (85%)
When a patient presents with new respiratory symptoms while using a medication known to cause DI-ILD, and should
initial investigations and treatment not resolve the clinical scenario, investigations should not routinely include
transbronchial lung biopsy
29 (88%)
When a patient presents with new respiratory symptoms while using a medication known to cause DI-ILD, and should
initial investigations and treatment not resolve the clinical scenario, investigations should not routinely include open
lung biopsy
28 (85%)
Prior to making any modification to drug therapy, discussion with colleagues that initiated therapy should occur to
ensure the safety of drug cessation and to consider alternative options
30 (91%)
In patients without significant hypoxia (oxygen saturation on room air ⩾94%), initial management should be to stop the
offending drug
28 (85%)
In patients with significant hypoxia (oxygen saturation on room air <94%), initial management should include drug
cessation and commencement of oral corticosteroid
28 (85%)
Recommended dosage of first line oral corticosteroid is prednisolone 0.5–1 mg·kg−1 28 (85%)
In patients with life threatening hypoxia due to presumptive DI-ILD, treatment should initially be with i.v.
methylprednisolone
31 (94%)
Recommended doses of i.v. methylprednisolone are 500–1000 mg once daily for 3 successive days 30 (91%)
Long term monitoring of response should include assessment of symptoms, pulmonary physiology (spirometry/
transfer factor), blood tests (if appropriate) and radiology (chest radiography, HRCT; dependent on presence or
absence of abnormalities on chest radiography that can be reliably monitored)
33 (100%)
In patients showing response to therapy, consideration of weaning of medication to lowest dose that controls disease
activity (which may include no treatment) should occur at 2–4 weekly intervals
28 (85%)
In patients that respond to initial corticosteroid therapy, and following a weaning protocol cannot be reduced to levels
of oral prednisolone (or equivalent) of <20 mg once daily, a steroid sparing agent should be considered
27 (82%)
Steroid sparing agents may include mycophenolate mofetil (preferred), azathioprine, methotrexate or
cyclophosphamide
25 (76%)
If a drug has been proven, or is highly suspected, to have caused DI-ILD, unless no alternative agent is available and
treatment is absolutely required, the offending drug should not be re-used
31 (94%)
If a patient has experienced a DI-ILD in the past, careful consideration of the likelihood or possibility of further DI-ILD
from future therapeutic interventions should be considered. If possible, the use of agents not known to be
associated with DI-ILD should be selected.
26 (79%)
DI-ILD: drug-induced interstitial lung disease; ILD: interstitial lung disease; MDT: multidisciplinary team; HRCT: high-resolution computed
tomography.
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“disagreed” or “strongly disagreed” that pulsed i.v. cyclophosphamide should be considered in those
patients not responding to i.v. methylprednisolone or oral prednisolone.
Of the 28 drugs associated with a significant risk of DI-ILD that were reviewed, only 10 advised on the use
of corticosteroids to treat suspected or confirmed cases of DI-ILD. The manufacturers of six of these
medications advise treatment with initial doses of 1–2 mg·kg−1·day−1 prednisolone which is at least double
the initial dose that the physicians in our surveys favoured. The manufacturers of one of the 10 drugs
TABLE 3 Statements not achieving consensus when agree and strongly agree is combined as one answer
Statement Responses: agree or
strongly agree
When a patient presents with new respiratory symptoms while using a medication known to cause DI-ILD, initial
investigations and management should focus around more common causes of symptoms
16 (49%)
Pulsed i.v. cyclophosphamide should be considered in those patients not responding to i.v. methylprednisolone or
oral prednisolone
14 (42%)
In patients responding to therapy, follow-up should occur within 6 weeks of initial therapy 24 (73%)
If a drug has been proven, or is highly suspected, to have caused DI-ILD, if no alternative agent is available and
treatment is absolutely required, the offending drug should be cautiously reintroduced ideally at reduced dosage
and with frequent monitoring (1–2 weekly)
19 (58%)
DI-ILD: drug-induced interstitial lung disease.
Structured clinical assessment (history, examination)
Is there a temporal relationship between commencing a drug known to cause 
DI-ILD and symptom onset?
Yes No
No Yes
Involvement of a specialist ILD MDT
Consider BAL with samples sent to exclude infection (typical/atypical) and examined for differential 
cell count
Initial investigations
1) Chest radiography 2) HRCT thorax 3) PFTs (spirometry and DLCO) 4) Blood tests
Consider alternative diagnosis
Radiological abnormalities consistent with ILD
(e.g. ground glass change, fibrosis)
and
restrictive defect on spirometry and/or DLCO
Blood tests suggestive of infection (significantly
raised inflammatory markers) or underlying CTD
(positive for specific autoantibody, especially if 
signs/symptoms of CTD present)
Sample positive for infection BAL lymphocytosis (>40%)
Sample negative for infection 
and BAL lymphocytosis (<40%)
Treat infection and consider
repeat HRCT in 6–8 weeks
Consider other diagnosis (e.g. 
hypersensitivity pneumonitis)
High probability of DI-ILD
(especially if BAL eosinophils)
FIGURE 1 Diagnostic algorithm for drug-induced interstitial lung disease (DI-ILD). HRCT: high-resolution
computed tomography; PFT: pulmonary function test; DLCO: diffusing capacity of the lung for carbon
monoxide; ILD: interstitial lung disease; CTD: connective tissue disease; MDT: multidisciplinary team; BAL:
bronchoalveolar lavage.
https://doi.org/10.1183/23120541.00286-2019 6
INTERSTITIAL LUNG DISEASE | J.A. EADEN ET AL.
advise treatment with initial doses of 40–60 mg·day−1 prednisolone which is more in keeping with the
results of our surveys. The three remaining manufacturers did not comment on a specific dose of
corticosteroid. The ability to determine the role of corticosteroids in the treatment of DI-ILD in a recent
systematic review was felt to be limited by a lack of randomised studies, as well as the problem of
incomplete data regarding the dose and duration of treatment and variation in both the eligibility criteria
for patient selection and corticosteroid dose [2]. The authors in this systematic review concluded that there
is currently insufficient evidence on which to base recommendations for the use of corticosteroids in
DI-ILD and that when corticosteroids are used, the dosing regimens used should be at the discretion of
the physician treating the patient. The consensus gained from our surveys significantly adds to the
literature, albeit ILD physicians’ opinion rather than being a prospective study.
Prior to making any modification to drug therapy, ensure that initiated therapy is safe/clinically appropriate 
to be stopped (may require slow drug wean) and consider alternative treatment options (if required)
In patients that respond to initial corticosteroid therapy and, following a weaning protocol, cannot be 
reduced to levels of oral prednisolone (or equivalent) of <20 mg once daily, consider a steroid sparing agent 
(e.g. mycophenolate mofetil (preferred), azathioprine, methotrexate or cyclophosphamide)
Does the patient have life-threatening hypoxia (e.g. requiring high concentration oxygen on HDU/ICU)?
Treat with i.v. methylprednisolone 500–1000 mg 
once daily for 3 successive days followed by 
prednisolone 0.5 mg·kg–1 for 2–4 weeks reducing 
by 5 mg every 1–2 weeks as tolerated
Does the patient have significant hypoxia
(oxygen saturation on room air <94%)?
Initial management:
stop the putative agent
Initial management: drug cessation and commencement 
of prednisolone 0.5 mg·kg–1 for 2–4 weeks reducing by 
5 mg every 1–2 weeks as tolerated
Yes
Yes
No
No
FIGURE 2 Treatment algorithm for drug-induced interstitial lung disease. HDU: high-dependency unit; ICU:
intensive care unit.
Physiology/radiography monitoring advised
Patient counselled on reporting risk
Advice on discontinuation in DI-ILD
Advice on dose reduction in DI-ILD
Advice on investigations
Advice on corticosteroid treatment
Risk of pulmonary toxicity stated
Black box warning
Respiratory monitoring advised
Drugs
50 10 15 20 25
27
14
18
22
17
13
10
3
7
30
FIGURE 3 Drugs with information on pulmonary toxicity included in the prescribing information (n=28).
DI-ILD: drug-induced interstitial lung disease.
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It is particularly notable that despite the recent advances in quantitative CT and magnetic resonance
imaging-based imaging biomarkers [9], that in the prescribing information the use of imaging for
monitoring is generally vague (often specifying only chest radiography) and non-quantitative. Imaging
biomarkers, with defined evidence-based cut-offs, already play a pivotal role in managing drug-induced
cardiotoxicity [10] and there seems to be a clear opportunity to similarly advance imaging biomarkers for
the management of DI-ILD.
We appreciate that there are limitations in our study. The number of physicians participating in the
surveys was relatively small and five of the 34 respondents in the first survey completed fewer than 50% of
the questions. The majority of the respondents in both surveys were based in the UK and therefore it
could be argued that the diagnostic and management approach to DI-ILD in the UK is over-represented
in the surveys. The information provided in the cases was limited and although descriptions of the CT
scans were included there were no actual CT images available to view. However, both surveys provided
expert consensus guidance that will help clinicians in the diagnosis and management of DI-ILD in which
the current evidence base is severely lacking. This is demonstrated by the limited information provided by
the manufacturers of the 28 drugs associated with a high risk of DI-ILD that we reviewed.
Conclusion
Our initial survey illustrates some significant differences in opinion between experienced ILD physicians
regarding the diagnosis and management of seven different ILD clinical scenarios. This may reflect the
lack of evidence or guidelines in DI-ILD and highlights the need for further research in this area to help
guide physicians. The results of the two surveys provide guidance for clinicians regarding an approach for
the diagnosis and management of DI-ILD. However, we recognise that treatment and follow-up of DI-ILD
needs to be individualised, including the consideration of the severity of disease and other comorbidities.
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